Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
出版年份 2017 全文链接
标题
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 110, Issue 1, Pages 40-48
出版商
Oxford University Press (OUP)
发表日期
2017-05-30
DOI
10.1093/jnci/djx134
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
- (2017) Richard G. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
- (2016) Marco Colleoni et al. JOURNAL OF CLINICAL ONCOLOGY
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
- (2016) Paul E. Goss et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence
- (2015) E.J. Blok et al. CANCER TREATMENT REVIEWS
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
- (2015) Jack Cuzick et al. LANCET ONCOLOGY
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
- (2014) Mustafa Al-Mubarak et al. PLoS One
- Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
- (2013) Jack Cuzick et al. LANCET
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
- (2012) Rakhshanda Layeequr Rahman et al. Cancers
- High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial
- (2011) D.B.Y. Fontein et al. EJSO
- Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover
- (2011) Huan Jin et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
- (2011) Cornelis JH van de Velde et al. LANCET
- Exemestane for Breast-Cancer Prevention in Postmenopausal Women
- (2011) Paul E. Goss et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17
- (2008) J. N. Ingle et al. ANNALS OF ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now